Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome

Leukemia and Lymphoma

Volumn 44, Issue 6, 2003, Pages 915-922

  Horiike, Shigeo ^a   Kita Sasai, Yuri ^a   Nakao, Mitsushige ^a   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Chromosome; IPSS; Myelodysplastic syndrome; NRAS; Prognosis; TP53

Indexed keywords

ALKYLATING AGENT; GYRASE INHIBITOR; HYDROXYUREA; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; BLAST CELL; BONE MARROW DEPRESSION; CANCER RISK; CHROMOSOME ANALYSIS; CYTOPENIA; GENE MUTATION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; LEUKEMIA; MALIGNANT TRANSFORMATION; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; VALIDATION PROCESS;

GENES, P53; HUMANS; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037409886     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000067620     Document Type: Review

References (79)

1. Aul, C. and Giagounidis, A. (2002) "Application of single and multiple prognostic factors in the assessment of patients with the myelodysplastic syndromes", In: Bennett, J.M., ed, The Myelodysplastic Syndromes: Pathobiology and Clinical Management (Marcel Dekker Inc., New York), pp. 203-249.
2. Mufti, G.J., Stevens, J.R., Oscier, D.G., Hamblin, T.J. and Machin, D. (1985) "Myelodysplastic syndromes: a scoring system with prognostic significance", British Journal of Haematology 59, 425-433.
3. Sanz, G.F., Sanz, M.A., Vallespi, T. and Canizo, M. (1989) "Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients", Blood 74, 395-408.
4. Aul, C., Gatterman, N., Heyll, A. and Germing, U. (1992) "Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system", Leukemia 6, 52-59.
5. Morel, P., Hebbar, M., Lai, J.L. and Duhamel, A. (1993) "Cytogenetic analysis has strong prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases", Leukemia 7, 1315-1323.
6. Toyama, K., Ohyashiki, K., Yoshida, Y., Abe, T., Asano, S., Hirai, H., Hirashima, K., Hotta, T., Kuramoto, A., Kuriya, S., Miyazaki, T., Kakishita, E., Mizoguchi, H., Okada, M., Shirakawa, S., Takaku, F., Tomonaga, M., Uchino, H., Yasunaga, K. and Nomura, T. (1993) "Clinical implications of chromosomal abnormalities in 401 patients with MDS: a multicentric study in Japan", Leukemia 7, 499-508.
7. Oscier, D. (1987) "Myelodysplastic syndromes", Balliere's Clinical Haematology 1, 389-426.
8. Greenberg, P., Taylor, K., Larson, R., Koeffler, P., Negrin, R., Saba, H., Ganser, A., Jakubowski, A., Gabrilove, J., Mufti, G., Cruz, J., Hammond, W., Broudy, V., Langley, G.R., Keating, A., Vardiman, J., Lamborn, K. and Brown, S. (1993) "Phase III randomized multicenter trial of G-CSFs vs. observation for myelodysplastic syndromes", Blood 82, 196a (Abstract, Suppl. 1).
9. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. and Bennett, J. (1997) "International scoring system for evaluating prognosis in myelodysplastic syndromes", Blood 89, 2079-2088.
10. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. and Sultan, C. (1982) "Proposals for the classification of the myelodysplastic syndromes", British Journal of Haematology 51, 189-199.
11. Sanz, G.F. and Sanz, M.A. (1992) "Prognostic factors in myelodysplastic syndromes", Leukemia Research 16, 77-86.
12. Boogaerts, M.A., Verhoef, G.E.G. and Demuynck, H. (1996) "Treatment and prognostic factors in myelodysplastic syndromes", Balliere's Clinical Haematology 9, 161-183.
13. Maschek, H., Gutzmer, R., Choritz, H. and Georgii, A. (1994) "Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients", European Journal of Haematology 53, 280-287.
14. Cassano, E., Giordano, M., Riccardi, A., Coci, A. and Cazzola, M. (1990) "Myelodysplastic syndromes: a multiparametric study of prognostic factors and a proposed scoring system", Haematlogica 75, 141-145.
15. Anemia Study Group of the Ministry of Health and Welfare: Oguma, S., Yoshida, Y., Uchino, H., Maekawa, T., Nomura, T. and Mizoguchi, H. (1995) "Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases", Leukemia Research 19, 219-225.
16. Shimazaki, K., Ohshima, K., Suzumiya, J., Kawasaki, C. and Kikuchi, M. (2000) "Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes", British Journal of Haematology 110, 584-590.
17. Aul, C., Gattermann, N., Germing, U., Runde, V., Heyll, A. and Schneider, W. (1994) "Risk assessment in primary myelodysplastic syndromes: validation of the Dusseldolf score", Leukemia 8, 1906-1913.
18. Aul, C., Gattermann, N., Germing, U., Winkelmann, M., Heyll, A., Runde, V. and Schneider, W. (1994) "Serum deoxythymidine kinase in myelodysplastic syndromes", Cancer 73, 322-327.
19. Musto, P., Bodenizza, C., Falcone, A., D'Arena, G., Scalzulli, P., Perla, G., Modoni, S., Parlatore, L., Valvano, M.R. and Carotenuto, M. (1995) "Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia", British Journal of Haematology 90, 125-130.
20. Zwiezina, H., Herold, M., Schollenberger, S., Geissler, D. and Schmalzl, F. (1991) "Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF", British Journal of Haematology 79, 438-443.
21. Ogata, K., Yokose, N., An, E., Kamikubo, K., Tamura, H., Dan, K., Sakamaki, H., Onozawa, Y., Hamaguchi, H. and Nomura, T. (1996) "Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome", British Journal of Haematology 93, 45-52.
22. Ito, Y., Okabe-Kado, J., Honma, Y., Iwase, O., Shimamoto, T., Ohyashiki, J.H. and Ohyashiki, K. (2002) "Elevated plasma level of differentiation inhibitory factor nm23-H1 protein correlates with risk factors for myelodysplastic syndrome", Leukemia 16, 165-169.
23. Lai, R., Esrey, E., Shen, Y., Despa, S., Kantarjian, H., Beran, M., Maushouri, T., Quackenbuch, R.C., Ketating, M. and Albitar, M. (2002) "Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome", Cancer 94, 14-17.
24. Yunis, J.J., Lobel, M., Arnesen, M.A., Oken, M.M., Mayer, M.G., Rydell, R.E. and Brunning, R.D. (1988) "Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia", British Journal of Haematology 68, 189-194.
25. Horiike, S., Misawa, S., Taniwaki, M. and Abe, T. (1988) "Chromosome abnormalities and karyotypic evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis", Cancer 62, 1129-1138.
26. Suciu, S., Kuse, R., Weh, H.J. and Hossfeld, D.K. (1990) "Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome", Cancer Genetics & Cytogenetics 44, 15-26.
27. White, A.D., Hoy, T.G. and Jacobs, A. (1994) "Extended cytogenetic follow-up and clinical progress in patients with myelodysplastic syndromes", Leukemia & Lymphoma 12, 401-412.
28. Sole, F., Espinet, B., Sanz, G.F., Cervera, J., Calasanz, M.J., Luno, E., Prieto, F., Granada, I., Hernandez, J.M., Cigudosa, J.C., Diez, J.L., Bureo, E., Marques, M.L., Arranz, E., Rios, R., Climent, J.A.M., Vallespi, T., Florensa, L. and Woessner, S. (2000) "Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes", British Journal of Haematology 108, 346-356.
29. Estey, E., Keating, M., Pierce, S. and Beran, M. (1997) "Application of the international scoring system for myelodysplasia to M.D. Anderson patients", Blood 90, 2843-2845.
30. Balduini, C.L., Guarnone, R., Pecci, A., Centenara, E., Invernizzi, R. and Ascari, E. (1999) "The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution, Haematologica 84, 12-16.
31. Maes, B., Meeus, P., Michaux, L., Bijnens, L., Boogaerts, M., Hagemeijer, A., De Wolf-Peeters, C. and Verhoef, G. (1999) "Application of the International prognostic scoring system for myelodysplastic syndromes", Annals of Oncology 10, 825-829.
32. Belli, C., Acevedo, S., Bengio, R., Arrossagaray, G., Watman, N., Rossi, N., Garcia, J., Flores, G., Goldztein, S. and Larripa, I. (2002) "Detection of risk groups in myelodysplastic syndromes. A multicenter study", Haematologica 87, 9-16.
33. Kita-Sasai, Y., Horiike, S., Misawa, S., Kaneko, H., Kobayashi, M., Nakao, M., Nakagawa, H., Fujii, H. and Taniwaki, M. (2001) "International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome", British Journal of Haematology 115, 309-312.
34. Chang, K.L., O'Donnell, M.R., Slovak, M.L., Dagis, A.C., Arber, D.A., Niland, J.C. and Forman, S.J. (2002) "Primary myelodysplasia occurring in adults under 50 years old: a clinicopathologic study of 52 patients", Leukemia 16, 623-631.
35. Estey, E.H. (1998) "Prognosis and therapy of secondary myelodysplastic syndromes", Haematologica 83, 543-549.
36. Anderson, J.E. and Appelbaum, F.R. (1997) "Myelodysplasia and myeloproliferative disorders", Current Opinion of Hematology 4, 261-267.
37. Nevill, T.J., Fung, H.C., Shepherd, J.D., Horsman, D.E., Nantel, S.H., Klingemann, H.G., Forrest, D.L., Toze, C.L., Sutherland, H.J., Hogge, D.E., Naiman, S.C., Le, A., Brocington, D.A. and Barnett, M.J. (1998) "Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogenic bone marrow transplantation", Blood 92, 1910-1917.
38. Deeg, H.J., Shulman, H.M., Anderson, J.E., Bryant, E.M., Gooley,T.A., Slattery, J.T., Anasetti, C., Fefer, A., Storb, R. and Appelbaum, F.R. (2000) "Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age", Blood 95, 1188-1194.
39. Hirai, H., Okada, M., Mizuguchi, H., Mano, H., Kobayashi, Y., Nishida, J. and Takaku, F. (1988) "Relationship between an activated N-ras oncogene and chromosomal abnormality during leukemic progression from myelodysplastic syndrome", Blood 71, 256-258.
40. Bartram, C.R. (1992) "Molecular genetic aspects of myelodysplastic syndromes", Hematology/Oncology Clinics of North America 6, 557-570.
41. Paquette, R.L., Landaw, E.M., Pierre, R.V., Kahan, J., Lubbert, M., Lazcano, O., Isaac, G., McCormick, F. and Koeffler, H.P. (1993) "N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome", Blood 82, 590-599.
42. Horiike, S., Misawa, S., Nakai, H., Kaneko, H., Yokota, S., Taniwaki, M., Yamane, Y., Inazawa, J., Abe, T. and Kashima, K. (1994) "N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome", Leukemia 8, 1331-1336.
43. Gallagher, A., Darley, R. and Padua, R.A. (1997) "RAS and the myelodysplastic syndromes", Pathologie-Biologie (Paris) 45, 561-568.
44. Padua, R.A., Guinn, B.A., Al-Sabah, A.I., Smith, M., Taytor, C., Pettersson, T., Ridge, S., Carter, G., White, D., Oscier, D., Chevret, S. and West, R. (1998) "RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasia: a 10-year follow-up", Leukemia 12, 887-892.
45. Neubauer, A., Greenberg, P., Negrin, R., Ginzton, N. and Liu, E. (1994) "Mutations in the ras protooncogenes in patients with myelodysplastic syndromes", Leukemia 8, 638-641.
46. Constantinidou, M., Chalevelakis, G., Economopoulos, T., Kofa, M., Liloglou, T., Anastassiou, C., Yalouris, A., Spandidos, D.A. and Raptis, S. (1997) "Codon 12 ras mutations in patients with myelodysplastic syndrome: incidence and prognostic value", Annals of Hematology 74, 11-14.
47. Ridge, S.A., Worwood, M., Oscier, D., Jacobs, A. and Padua, R.A. (1990) "FMS mutations in myelodysplastic, leukemic, and normal subjects", Proceedings of the National Academy of Sciences USA 87, 1377-1380.
48. Horiike, S., Yokota, S., Nakao, M., Iwai, T., Sasai, Y., Kaneko, H., Taniwaki, M., Kashima, K., Fujii, H., Abe, T. and Misawa, S. (1997) "Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia", Leukemia 11, 1442-1446.
49. Bouscary, D., Preudhomme, C., Ribrag, V., Melle, J., Viguie, F., Picard, F., Guesnu, M., Fenaux, P., Gisselbrecht, S. and Dreyfus, F. (1995) "Prognostic value of c-mpl expression in myelodysplastic syndromes", Leukemia 9, 783-788.
50. Miyake, K., Inokuchi, K., Dan, K. and Nomura, T. (1993) "Expression of the DCC gene in myelodysplastic syndromes and overt leukemia", Leukemia Research 17, 785-788.
51. Uchida, T., Kinoshita, T., Nagai, H., Nakahara, Y., Saito, H., Hotta, T. and Murate, T. (1997) "Hypermethylation of the p15INK4B gene in myelodysplastic syndromes", Blood 90, 1403-1409.
52. Quesnel, B., Guillerm, G., Vereecque, R., Wattel, E., Preudhomme, C., Bauters, F., Vanrumbeke, M. and Fenaux, P. (1998) "Methylation of the p15INK4B gene in myelodysplastic syndromes is frequent and acquired during disease progression", Blood 91, 2985-2990.
53. Harris, C.C. and Hollstein, M. (1993) "Clinical implications of the p53 tumor-suppressor gene", New England Journal of Medicine 329, 1318-1327.
54. de Fromental, C.C. and Sorrssi, T. (1992) "TP53 tumor suppressor gene: a model for investigating human mutagenesis", Genes Chromosomes & Cancer 4, 1-15.
55. Prokocimer, M. and Rotter, V. (1994) "Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages", Blood 84, 2391-2411.
56. Ludwig, L., Schulz, A.S., Janssen, W.G., Gruenewald, K. and Bartram, C.R. (1992) "P53 mutations in myelodysplastic syndromes", Leukemia 6, 1302-1304.
57. Sugimoto, K., Hirano, N., Toyoshima, H., Chiba, S., Mano, H., Takaku, F., Yazaki, Y. and Hirai, H. (1993) "Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia", Blood 81, 3022-3026.
58. Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. and Fenaux, P. (1994) "p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies", Blood 84, 3148-3157.
59. Kaneko, H., Misawa, S., Horiike, S., Nakai, H. and Kashima, K. (1995) "TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities", Blood 85, 2189-2193.
60. Misawa, S. and Horiike, S. (1996) "TP53 mutations in myelodysplastic syndrome", Leukemia & Lymphoma 23, 417-422.
61. Castro, P.D., Liang, J.C. and Nagarajan, L. (2000) "Deletion of chomosome 5q13.3 and 17p loci cooperate in myeloid neoplasms", Blood 95, 2138-2143.
62. Lai, J.L., Preudhomme, C., Zandecki, M., Flactif, M., Vanrumbeke, M., Wattel, E. and Fenaux, P. (1995) "Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations", Leukemia 9, 370-381.
63. Nakai, H., Kaneko, H., Nakao, M., Horiike, S. and Misawa, S. (1994) "Is inactivation of the p53 gene a common event in leukemias and myelodysplastic syndrome with monosomy 17p?", Leukemia 8, 1247-1248.
64. Jary, L., Mossafa, H., Fourcade, C., Genet, P., Pulik, M. and Flandrin, G. (1997) "The 17p-syndrome: a distinct myelodysplastic syndrome entity?", Leukemia & Lymphoma 25, 163-168.
65. Soenen, V., Preudhomme, C., Roumier, C., Daudignon, A., Lai, J.L. and Fenaux, P. (1998) "17p deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ hybridization", Blood 91, 1008-1015.
66. Wang, P., Spielberger, R.T., Thangavelu, M., Zhao, N., Davis, E.M., Iannantouni, K., Larson, R.A. and LeBeau, M.M. (1997) "Dic(5;17): a recurring abnormality in malignant myloid disorders associated with mutations of TP53", Genes Chromosomes & Cancer 20, 282-291.
67. Merlat, A., Lai, J.L., Sterkers, Y., Demory, J.L., Bauters, F., Preudhomme, C. and Fenaux, P. (1999) "Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report of 25 cases", Leukemia 13, 250-257.
68. Kyle, R.A., Rierre, R.V. and Bayrd, E.D. (1970) "Multiple myeloma and acute myelomonocytic leukemia: report of four cases possibly related to melphalan", New England Journal of Medicine 283, 1121-1125.
69. Pedersen-Bjergaard, J., Andersen, M.K., Christiansen, D.H. and Nerlov, C. (2002) "Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia", Blood 99, 1909-1912.
70. Horiike, S., Misawa, S., Kaneko, H., Sasai, Y., Kobayashi, M., Fujii, H., Tanaka, S., Yagita, S., Abe, T., Kashima, K. and Taniwaki, M. (1999) "Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype", Leukemia 13, 1235-1242.
71. Christiansen, D.H., Anderson, M.K. and Pedersen-Bjergaard, J. (2001) "Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis", Journal of Clinical Oncology 19, 1405-1413.
72. Imamura, N., Abe, K. and Oguma, N. (2002) "High incidence of point mutations of p53 suppressor oncogene in patients with myelodysplastic syndrome among atomic-bomb survivors: a 10-year follow-up", Leukemia 16, 154-156.
73. Ben-Yehuda, D., Krichevsky, S., Caspi, O., Rund, D., Polliack, A., Abeliovich, D., Zelig, O., Yahalom, V., Paltiel, O., Or, R., Peretz, T., Ben-Neriah, S., Yehuda, O. and Rachmilewitz, E.A. (1996) "Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype", Blood 88, 4296-4303.
74. Andersen, M.K., Christiansen, D.H., Kirchhoff, M. and Pedersen-Bjergaard, J. (2001) "Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and MDS, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents", Genes, Chromosomes & Cancer 31, 33-41.
75. Sterkers, Y., Preudhomme, C., Lai, J.L., Demory, J.L., Caulier, M.T., Wattel, E., Bordessoule, D., Bauters, F. and Fenaux, P. (1998) "Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion", Blood 91, 616-622.
76. Felix, C.A., Hosler, M.R., Provisor, D., Salhany, K., Sexsmith, E.A., Slater, D.J., Cheung, N.K.V., Winick, N.J., Strauss, E.A., Heyn, R., Lange, B.J. and Malkin, D. (1996) "The p53 gene in pediatric therapy-related leukemia and myelodysplasia", Blood 87, 4376-4381.
77. Cox, D.R. (1972) "Regression models and life tables", Journal of the Royal Statistical Society 34, 187-220.
78. Wen, W.H., Bernstein, L., Lescallett, J., Beazer-Barclay, Y., Sullivan-Halley, J., White, M. and Press, M.F. (2000) "Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis", Cancer Research 60, 2716-2722.
79. Huber, M., Losert, D., Hiller, R., Harwanegg, C., Mueller, M.W. and Schmidt, W.M. (2001) "Detection of single base alterations in genomic DNA by solid phase polymerase chain reaction on oligonucleotide microarrays", Analytical Biochemistry 299, 24-30.